Phase II study of ifosfamide plus daily oral etoposide in previously treated ovarian cancer: A Hoosier Oncology Group (HOG) study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 27, Issue 3, 2004, Pages 229-231

  Shaheen, Montaser ^a   Stender, Michael J ^a,b   McClean, John W ^c   Look, Katherine Y ^a   Einhorn, Lawrence H ^a,d  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^b Hem/Onc Consultants PC   (United States)

^c Medical and Surgical Specialists LLC   (United States)

^d Hoosier Oncology Group   (United States)

Author keywords

Combination chemotherapy; Etoposide; Ifosfamide; Recurrent ovarian cancer

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; PACLITAXEL; TOPOTECAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GRANULOCYTOPENIA; HUMAN; INFECTION; KAPLAN MEIER METHOD; LIVER TOXICITY; LUNG TOXICITY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PHASE 2 CLINICAL TRIAL; RECURRENT CANCER; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; HUMANS; IFOSFAMIDE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 2942618191     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.COC.0000054896.56416.79     Document Type: Article

References (25)

1. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
2. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92:699-708.
3. Deppe G, Baumann P. Advances in ovarian cancer chemotherapy. Curr Opin Oncol 2000;12:481-91.
4. Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist 2000;5:26-35.
5. Cremers GJ, Bolis G, Gore M, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 1996;14:3056-61.
6. Bookman MA, Malmstrom H, Bolis G, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy containing cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998;16:3345-52.
7. Lund B, Hansen OP, Theilade K, et al. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. Cancer Inst 1994;86:1530.
8. Shapiro JD, Millward MJ, Sischin D, et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 1996;63:89-93.
9. Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997;15:987-93.
10. Bajetta E, Di Leo A, Biganzoli L, et al. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 1996;14:2546-51.
11. George MJ, Heron JF, Kerbrat P, et al. Navelbine in advanced ovarian epithelial cancer: a study of the French Oncology centers. Semin Oncol 1989;16(suppl 4):30-2.
12. Rose PG, Blessing JA, Mayer AR, et al. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1998;16:405-10.
13. Hoskins PJ, Swenerton KD. Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 1994;12:60-3.
14. Sutton GP, Blessing JA, Homesley HD, et al. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1989;7:1672-7.
15. Sorenson P, Pfeiffer P, Bertelsen K. A phase 2 trial of ifosfamide/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapy. Gynecol Oncol 1995;56:75-8.
16. Sabbatini P, Sprongs D. Salvage therapy for ovarian cancer. Oncology 1998;12:833-44.
17. Loehrer PJ Sr, Einhorn LH, Williams SD. VP-16 plus ifosfamide 1986 plus cisplatin as salvage therapy in refractory germ cell cancer. J Clin Oncol 1986;4:528-36.
18. Van Hoff J, Grier HE, et al. Etoposide, ifosfamide, and cisplatin in refractory childhood solid tumors. Response and toxicity. Cancer 1995;1:1686.
19. Ozols RF. Treatment of recurrent ovarian cancer: increasing options - 'recurrent' results. J Clin Oncol 1997;15:2177-8.
20. Slevin ML, Clark PI, et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J Clin Oncol 1989;7:1333-40.
21. Einhom LH. Daily oral etoposide in the treatment of cancer. Semin Oncol 1991;18(suppl 2):43-7.
22. Bruzzone M, Campora E, Merlini L, et al. Ifosfamide and etoposide salvage treatment in advanced ovarian cancer. J Chemother 1991;3:332-4.
23. Trope C, Kaern J, Vergote I, et al. A phase II study of etoposide combined with ifosfamide as second-line therapy in cisplatin-resistant ovarian carcinomas. Cancer Chemother Pharmacol 1990;26(suppl): S45-7.
24. Aravantinos G, Dimopoulos MA, Kosmidis P, et al. Ifosfamide plus oral etoposide salvage chemotherapy for platinum-resistant paclitaxel-pretreated ovarian cancer. Ann Oncol 2000;11:607-12.
25. Vanhoefer U, Schleucher N, Klaassen U, et al. Ifosfamide-based drug combination: preclinical evaluation of drug interaction and translation into the clinic. Semin Oncol 2000;27(suppl 1):8-13.